serena williams ro glp 1 📄 Inside Williams’ partnership with @ro.co for GLP-1s, It’s a grand slam partnership for telehealth provider Ro. World renowned tennis star @serenawilliams is partnering with the brand as its Serena Williams Joins Ro as

Description

The HR for the expanded MACE outcome was similar to that of the primary outcome (HR 0.82

Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Dulaglutide is a long-acting GLP-1RA used for T2DM with demonstrated cardiovascular benefits.[10] Liraglutide, another long-acting GLP-1RA, is used for T2DM and obesity management and is under investigation for Alzheimers disease and metabolic-associated hepatic steatosis.[4] Lixisenatide, a short-acting GLP-1RA, shows comparable efficacy to exenatide and liraglutide for T2DM management, and is now combined with insulin glargine.[23] Semaglutide, available in injectable and oral forms, has demonstrated benefits in promoting weight loss, reducing risk of cardiovascular events, and slowing progression of diabetic CKD.[24] Finally, tirzepatide is a dual agonist for receptors of GLP and glucose-dependent insulinotropic polypeptide (GIP), a hormone released from the intestines in response to macronutrients.[25] These two mechanisms of action have synergistic glucose-lowering and weight loss effects with lower side effect rates than other GLP-1RAs.[25] Tirzepatide has also been shown to result in blood pressure reduction, obstructive sleep apnea control, and improved cholesterol in T2DM patients.[5] Table

Clinical Evidence for GLP-1 Use in Menopause While most GLP-1 research has focused on people with type 2 diabetes or general weight management, emerging evidence suggests particular benefit for women navigating menopausal metabolic changes

Popular GLP-1 Medications The GLP-1 landscape includes several widely prescribed options: Semaglutide (Ozempic, Wegovy): For type 2 diabetes and weight management Tirzepatide (Mounjaro): A dual GIP/GLP-1 receptor agonist with significant weight loss effects Liraglutide (Saxenda): Approved specifically for weight management Dulaglutide (Trulicity): Primarily used for type 2 diabetes management Each medication has a unique dosing schedule and side effect profile that your healthcare provider can discuss during personalized consultations